Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient

Monoclonal antibodies that block PD1 or PDL1 are among the most-promising immunotherapies available in advanced cancers, including pembrolizumab and nivolumab for melanoma and non-small-cell lung cancer (NSCLC) [1–5]. Adverse events related to anticancer immunotherapy have been extensively investigated; we report the first case, to our knowledge, of cryoglobulinemia associated with the use of anti-PD-1 antibody, nivolumab, in patient affected by advanced NSCLC.

http://ift.tt/2rt53hT